Pfizer (PFE -3.85%) and its German partner BioNTech (BNTX -1.57%) reported incredible efficacy data from a phase 3 trial for their mRNA coronavirus vaccine candidate. This news, paired with the equally impressive data from Moderna (MRNA -2.45%) about its candidate that takes a similar approach, inspired much hope around the world and injected optimism into the stock market.
The Motley Fool talked to Dr. Leo Nissola about how investors should decide whether to buy stocks of these companies.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of October 20, 2020
Corinne Cardina: My last question for you, because The Motley Fool, we are investors, what might you say to any investors who are considering buying stock of a company that's working on a COVID vaccine, particularly the mRNA vaccine? So Pfizer, BioNTech, Moderna, do you have any tips?
Dr. Leo Nissola: I wish I did, but I don't really. I usually make my choices based on past successes. If a company was able to produce blockbuster drugs that have saved millions of people's lives, that have time and time and again, being on the right side of history, supporting science, advancing treatments, that would tell me that I would trust that company.
Cardina: Yes, absolutely. Looking at their track record is critical to making any investment decision.
